A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

The most common side effects of GLP-1 medicines are related to digestion: nausea, vomiting, diarrhoea, indigestion, stomach ...

Oral semaglutide did not significantly reduce disease progression in patients with early Alzheimer disease, according to results from two phase 3 trials.

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an ...

The authors conclude that early use of semaglutide may serve as an effective adjunctive strategy to mitigate the metabolic burden associated with SGAs. By intervening during the initial stages of ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans ...